Adaptimmune Therapeutics’ (ADAP) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Adaptimmune Therapeutics (NASDAQ:ADAP) in a report released on Tuesday, MarketBeat.com reports.

A number of other equities analysts have also weighed in on ADAP. Wall Street Zen started coverage on shares of Adaptimmune Therapeutics in a research note on Friday, May 16th. They issued a “buy” rating for the company. Mizuho lowered shares of Adaptimmune Therapeutics from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $1.50 to $0.50 in a research note on Thursday, June 26th. Barclays reduced their target price on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an “underweight” rating for the company in a research note on Wednesday, May 14th. Wells Fargo & Company reduced their target price on shares of Adaptimmune Therapeutics from $1.50 to $1.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 14th. Finally, Jones Trading lowered shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 11th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Adaptimmune Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $1.35.

Adaptimmune Therapeutics Price Performance

ADAP opened at $0.10 on Tuesday. The company has a quick ratio of 1.79, a current ratio of 2.02 and a debt-to-equity ratio of 4.24. Adaptimmune Therapeutics has a 12 month low of $0.10 and a 12 month high of $1.48. The company has a fifty day simple moving average of $0.26 and a 200 day simple moving average of $0.36. The stock has a market cap of $27.80 million, a P/E ratio of -0.39 and a beta of 2.18.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.18) EPS for the quarter, meeting analysts’ consensus estimates of ($0.18). Adaptimmune Therapeutics had a negative net margin of 38.91% and a negative return on equity of 163.73%. The business had revenue of $7.29 million during the quarter, compared to analysts’ expectations of $6.55 million. On average, research analysts expect that Adaptimmune Therapeutics will post -0.14 EPS for the current year.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC raised its holdings in shares of Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after purchasing an additional 869,949 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Adaptimmune Therapeutics by 492.0% in the 4th quarter. Two Sigma Advisers LP now owns 70,735 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 58,787 shares during the period. Jane Street Group LLC raised its holdings in shares of Adaptimmune Therapeutics by 87.7% in the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 152,780 shares during the period. Two Seas Capital LP bought a new stake in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $7,992,000. Finally, Long Focus Capital Management LLC raised its holdings in shares of Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after purchasing an additional 7,194,503 shares during the period. 31.37% of the stock is owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.